AU2006220626A1 - Methods and compositions for treating cancer - Google Patents

Methods and compositions for treating cancer Download PDF

Info

Publication number
AU2006220626A1
AU2006220626A1 AU2006220626A AU2006220626A AU2006220626A1 AU 2006220626 A1 AU2006220626 A1 AU 2006220626A1 AU 2006220626 A AU2006220626 A AU 2006220626A AU 2006220626 A AU2006220626 A AU 2006220626A AU 2006220626 A1 AU2006220626 A1 AU 2006220626A1
Authority
AU
Australia
Prior art keywords
cancer
ebselen
allopurinol
cisplatin
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006220626A
Other languages
English (en)
Inventor
Jonathan Kil
Eric Daniel Lynch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sound Pharmaceuticals Inc
Original Assignee
Sound Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sound Pharmaceuticals Inc filed Critical Sound Pharmaceuticals Inc
Publication of AU2006220626A1 publication Critical patent/AU2006220626A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2006220626A 2005-03-08 2006-03-08 Methods and compositions for treating cancer Abandoned AU2006220626A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66142905P 2005-03-08 2005-03-08
US60/661,429 2005-03-08
PCT/US2006/008201 WO2006096759A2 (fr) 2005-03-08 2006-03-08 Methodes et compositions destinees a traiter le cancer

Publications (1)

Publication Number Publication Date
AU2006220626A1 true AU2006220626A1 (en) 2006-09-14

Family

ID=36954000

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006220626A Abandoned AU2006220626A1 (en) 2005-03-08 2006-03-08 Methods and compositions for treating cancer

Country Status (8)

Country Link
US (2) US20060211745A1 (fr)
EP (1) EP1855662A4 (fr)
JP (1) JP2008533021A (fr)
KR (1) KR20070113262A (fr)
CN (1) CN101160121B (fr)
AU (1) AU2006220626A1 (fr)
CA (1) CA2600134A1 (fr)
WO (1) WO2006096759A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080207679A1 (en) * 2007-02-16 2008-08-28 Noah Berkowitz Glutathione peroxidase mimetics for the treatment of dermatoses
US20080234283A1 (en) * 2007-02-16 2008-09-25 Noah Berkowitz Glutathione peroxidase mimetics for treatment of neurodegenerative, pulmonary and inflammatory diseases
GB0916010D0 (en) * 2009-09-11 2009-10-28 Isis Innovation JMJD2 demethylase inhibitors
GB201102248D0 (en) 2011-02-09 2011-03-23 Isis Innovation Treatment of bipolar disorder
US9085598B2 (en) 2011-10-28 2015-07-21 The Royal Institution For The Advancement Of Learning/Mcgill University Compounds targeting the cell invasion protein complex, their pharmaceutical compositions and methods of use thereof
KR20150130451A (ko) * 2013-03-15 2015-11-23 제넨테크, 인크. 암 치료 방법 및 항암제 내성 예방을 위한 방법
EP3160465A4 (fr) * 2014-06-24 2017-12-20 The Board of Trustees of the Leland Stanford Junior University Utilisation de petites molécules pour le traitement d'une toxicité à clostridium difficile
GB2550110A (en) 2016-04-28 2017-11-15 Univ Oxford Innovation Ltd Treatment of impulsivity-related disorders
CN107714650A (zh) * 2016-08-11 2018-02-23 杭州健昵福生物科技有限公司 一种含谷氨酰胺代谢抑制剂脂质体及其药物组合物与用途
GB201717629D0 (en) 2017-10-26 2017-12-13 Univ Oxford Innovation Ltd Treatment of unipolar depressive disorder
US20210267984A1 (en) * 2018-09-03 2021-09-02 Wei Zhu Application of allopurinol in preparation of drug for treating cancer with high expression of paics gene

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3027073C2 (de) * 1980-07-17 1985-03-07 A. Nattermann & Cie GmbH, 5000 Köln Pharmazeutische Präparate, enthaltend 2-Phenyl-1,2-benzisoselenazol-3(2H)-on
EP0199986B1 (fr) * 1985-04-27 1990-04-25 A. Nattermann & Cie. GmbH Dérivés benzisosélénazolonyliques, leur procédé de préparation et compositions pharmaceutiques les contenant
DE3638124C2 (de) * 1986-11-08 1996-09-05 Nattermann A & Cie Neue pharmazeutische Verwendung von Ebselen
US5385726A (en) * 1990-08-06 1995-01-31 Rhone-Poulenc Rorer Gmbh Use of 2-phenyl-1,2-benzisoselenazol-3-(2H)-one
DE4024885C2 (de) * 1990-08-06 2002-07-18 Nattermann A & Cie Verwendung von 2-Phenyl-1,2-benzisoselenazol-3(2H)-on
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6177434B1 (en) * 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6093743A (en) * 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6601580B1 (en) * 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
WO2003045334A2 (fr) * 2001-11-29 2003-06-05 Sound Pharmaceuticals Incorporated Methodes et compositions permettant de diminuer les effets indesirables de la chimiotherapie
AU2002357193A1 (en) * 2001-12-19 2003-07-09 Smithkline Beecham Corporation Thienopyrimidine compounds as protein tyrosine kinase inhibitors
US6815434B2 (en) * 2002-01-04 2004-11-09 Sound Pharmaceuticals Incorporated Methods for treating hearing loss
US6702850B1 (en) * 2002-09-30 2004-03-09 Mediplex Corporation Korea Multi-coated drug-eluting stent for antithrombosis and antirestenosis
US7208514B2 (en) * 2003-03-13 2007-04-24 Mitsubishi Pharma Corporation Tumorigenesis inhibitor
US20050147978A1 (en) * 2003-12-30 2005-07-07 Jose Remacle Method for quantitative determination of multi-drug resistance in tumors

Also Published As

Publication number Publication date
JP2008533021A (ja) 2008-08-21
EP1855662A2 (fr) 2007-11-21
WO2006096759A3 (fr) 2007-04-05
WO2006096759A2 (fr) 2006-09-14
CN101160121A (zh) 2008-04-09
EP1855662A4 (fr) 2009-12-23
US20110020470A1 (en) 2011-01-27
CN101160121B (zh) 2012-05-23
KR20070113262A (ko) 2007-11-28
CA2600134A1 (fr) 2006-09-14
US20060211745A1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
US20110020470A1 (en) Methods and compositions for treating cancer
US8309560B2 (en) Methods and compositions for ameliorating the undesirable effects of chemotherapy
Hothi et al. High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells
JP6090836B2 (ja) 化学療法剤の抗腫瘍活性増強剤
EP1322654B1 (fr) Complexes de platine tenant lieu d'agents antitumoraux
US20200405752A1 (en) Antitumor agent, antitumor effect enhancer, and antitumor kit
US11981690B2 (en) Alkyl-terminated thiocarbamate complex and method for treating cancer
Wang et al. New Platinum (II) agent induces bimodal death of apoptosis and autophagy against A549 cancer cell
McKeage et al. Platinum and other metal coordination compounds in cancer chemotherapy. A commentary on the sixth international symposium: San Diego, California, 23-26th January 1991
Facchetti et al. Malignant Pleural Mesothelioma: State of the art and advanced cell therapy
Ryan et al. A trans-Pt (ii) hedgehog pathway inhibitor complex with cytotoxicity towards breast cancer stem cells and triple negative breast cancer cells
US7268245B2 (en) Multinuclear platinum compounds
US20240059719A1 (en) Gold complexes as anticancer agent
US11571430B2 (en) Platinum(II) ammine selenourea complexes and methods of treating cancer
NZ740252B2 (en) Antitumor agent including low-dose irinotecan hydrochloride hydrate

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted